First‐line or second‐line PD‐1 inhibition in advanced oesophageal squamous cell carcinoma: A prospective, multicentre, registry study

2022 ◽  
Author(s):  
Xu‐Yuan Li ◽  
Li‐Sheng Huang ◽  
Hao‐Quan Cai ◽  
Wan‐Lan Huang ◽  
Xiao‐Long Huang
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Second Line ◽  
Oesophageal Squamous Cell Carcinoma ◽  
Registry Study ◽  
First Line

scholarly journals First-line versus second-line immunotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck

2019 ◽  
Vol 30 ◽  
pp. v462
Author(s):  
C. Even ◽  
N. Torossian ◽  
T. Ibrahim ◽  
N. Martin ◽  
L. Mayache Badis ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Second Line ◽  
First Line ◽  
Metastatic Squamous Cell Carcinoma

Methotrexate and cetuximab for metastatic advanced head and neck squamous cell carcinoma.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e17033-e17033
Author(s):  
Bassel Atassi ◽  
George H. Yoo ◽  
Natasha Robinette ◽  
Khaled Sibai ◽  
Ammar Sukari
Keyword(s):  
Overall Survival ◽  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Palliative Chemotherapy ◽  
Single Agent ◽  
Neck Squamous Cell Carcinoma ◽  
Second Line ◽  
First Line

e17033 Background: After the failure of first-line palliative chemotherapy in recurrent non-resectable or metastatic head and neck squamous-cell carcinoma (HNSCC), there is no standard of care second-line treatment that is proven to improve quality of life or prolong survival. Both methotrexate and cetuximab has shown a single-agent activity in advanced HNSCC. We are presenting our institutional experience in using unique combination chemotherapy with methotrexate plus cetuximab (MC). Methods: Retrospectively, single institution’s charts were reviewed from 2004-2010, all patients have documented recurrent non-resectable or metastatic HNSCC. After failing at least one line of palliative chemotherapy, patients received weekly IV methotrexate 25 mg/m2 plus IV cetuximab 400 mg/m2 loading dose at week one followed by 250 mg/m2 maintenance dose weekly. Each cycle is 4 weeks treatments. Patients who completed at least 2 cycles were included in the study. Patients can receive MC as first line if they have poor performance status. Treatment was continued until progression. Results: Total of 34 patients were included in the study, 26 male and 8 female, 18 African American and 16 Caucasian. Median patient age was 60 years old. 18, 6 and 6 patients received MC as second, third and fourth line therapy, respectively. 4 patients received MC as first line because there were not candidates for more aggressive chemotherapeutic regimens. The average received number of weekly treatments was 25 (8-69) and average number of cycles was 6 (2-17). Prior chemotherapy regimens include taxanes, platinum, 5-flurouracil, and gemcitabin. Median progression free survival was 4.9 months and overall survival was 10.7 months. Overall survival based on race was 9.9 months for Caucasians and 10.7 months for African Americans (P=0.0391). Grade I and II skin rash was observed in 41% of patients, no grade III/IV toxicities were noticed. Conclusions: Methotrexate plus cetuximab is a well tolerated regimen with a significant survival benefit. Prospective studies are warranted in order to evaluate this regimen as a second line palliative therapy for patients with advanced non-curable head and neck squamous cell carcinoma.

Sign in / Sign up

Export Citation Format

Share Document